As NRAS p.(Gln61Lys) is a well-known driver mutation, described in various cancer types and associated with malignancy and tumor progression, the effect of this mutation in our in vitro-model was analyzed to investigate whether it is solely sufficient for the development of TKI resistance and if this effect is detectable with our in vitro-model (Supplementary Table S3). The gene discussed is NRAS; the disease is cancer.